IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9

PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21

(2012) Julia Hoefer et al.   AMERICAN JOURNAL OF PATHOLOGY

Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma

(2012) Adil Daud et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Advanced prostate cancer—a case for adjuvant differentiation therapy

(2012) Jayant K. Rane et al.   Nature Reviews Urology

Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion

(2012) Lukasz Hudak et al.   PROSTATE

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence

(2011) Hitoshi Ishiguro et al.   CANCER SCIENCE

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

(2011) Jayaprakash Karkera et al.   PROSTATE

Cytokine disbalance in common human cancers

(2010) Zoran Culig   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

(2009) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Redefining the role of interferon in the treatment of malignant diseases

(2009) Sergio Bracarda et al.   EUROPEAN JOURNAL OF CANCER

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

(2009) S. Feng et al.   MOLECULAR CANCER THERAPEUTICS